Symptomatic therapy of multiple sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 90-104

  Markowitz, Clyde ^a  

^a EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMANTADINE; AMITRIPTYLINE; AMPYRA; BACLOFEN; BETHANECHOL; CARBAMAZEPINE; DANTROLENE; DARIFENACIN; DESIPRAMINE; DIAZEPAM; DULOXETINE; GABAPENTIN; METHYLPREDNISOLONE; MODAFINIL; OXYBUTYNIN; PAPAVERINE; PHENYTOIN; PREDNISONE; PREGABALIN; PROPANTHELINE BROMIDE; PROPRANOLOL; PROSTAGLANDIN E1; SILDENAFIL; SOLIFENACIN; TADALAFIL; TIZANIDINE; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

ARTICLE; ATAXIA; BLADDER DYSFUNCTION; BLADDER SPASM; COGNITIVE DEFECT; DECUBITUS; DETRUSOR DYSSYNERGIA; DRUG MEGADOSE; DYSPHAGIA; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; EXERCISE; FACE PAIN; FATIGUE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTONIC BLADDER; INCONTINENCE; LIVER TOXICITY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYELITIS; NEUROGENIC BOWEL; OCCUPATIONAL THERAPY; OPTIC NEURITIS; OSTEOPENIA; PAIN; PALLIATIVE THERAPY; PHYSIOTHERAPY; RADIOSURGERY; RHIZOTOMY; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SPASTICITY; TREMOR; TRIGEMINUS NEURALGIA; UHTHOFF SYNDROME; URINARY URGENCY; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEAKNESS; XEROSTOMIA;

EID: 78650727369     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389936.61789.04     Document Type: Article

References (26)

1. Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM. Baclofen for spasticity in multiple sclerosis: Double blind crossover and three year study. Neurology 1978;28(11):1094-1098.
2. Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44(11 suppl 9):S53-S59.
3. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81(2):164-169.
4. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517- 1526.
5. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27(2):186-192.
6. van Diemen HAM, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32(2):123-130.
7. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994;51(3):292-296.
8. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-738.
9. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000;55(5 suppl 1):41-46.
10. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995;45(7):1294-1296.
11. Espir MLE, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970;33(4):528-531.
12. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12(3):251-254.
13. Schwid SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple sclerosis: Current understanding and future directions. J Rehabil Res Dev 2002;39(2):211-224.
14. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14(3):273-278.
15. Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005;64(7):1267-1269.
16. Bittar RG, Hyam J, Nandl D, et al. Thalamotomy versus thalamic stimulation for multiple sclerosus tremor. J Clin Neurosci 2005;12(6):638-642.
17. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbrated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 1998;339(19):1408.
18. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: A case-control study, I: Frequency and comparison of groups. Mult Scler 1999;5(6):418-427.
19. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59(5):780-787.
20. Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. J Rehabil Res Dev 2006;43(1):83-90.
21. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63(9):1579-1585.
22. Krupp LB, Christodoulou C, Melville P, et al. A multi-center randomized clinical trial of donepezil to treat memory impairment in multiple sclerosis [AAN abstract S21.004]. Neurology 2010;74(suppl 2):A294.
23. Ozgocmen S, Bulut S, Ilhan N, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: Effect of ambulatory status and functional capacity. J Bone Miner Metab 2005;23(4):309-313.
24. Redelings MD. Lee NE, Sorvillo F. Pressure ulcers: More lethal than we thought? Adv Skin Wound Care 2005;18(7):367-372.
25. Romero DV, Treston J, O'Sullivan AL. Raising awareness of pressure ulcer prevention and treatment. Adv Skin Wound Care 2006;19(7):398-405.
26. Prosiegel M, Schelling A, Wagner-Sonntag E. Dysphagia and multiple sclerosis. Int MS J 2004;11(1):22-31.